Given the well-established notion that patients with both complex karyotype and mutant TP53 have a particularly dismal prognosis (6, 9), it is tempting to speculate that the CR rate expected in the population enrolled in the present trial, when treated with a 10-day course of decitabine alone, is lower than our original prediction, which was based on patients with AML with mutant TP53 who may or may not have had complex karyotype. Here, TP53 is linked to acute myeloid leukemia.